2 0 2 5年4月8日，上海交通大学迎来了1 2 9周年生日。 1 8 9 6年，上海交通大学以南洋公学之名创立于民族危难之际，秉承"自强首在储才，储才必先 兴学"建校理念，率先形成中西融汇、求实致用的教育思想，开中国近代新式教育之先河。跨 越三个世纪的上海交通大学，因图强而生、因改革而兴、因人才而盛。建校1 2 9年以来，奋战 在各地、各行各业的交大人，为祖国繁荣昌盛和人类社会进步作出了卓越贡献。 交大创造了中国近现代发展史上的诸多 "第一"：中国最早的内燃机、最早的电机、最早的中文 打字机等；新中国第一艘万吨轮、第一艘核潜艇、第一艘气垫船、第一艘水翼艇、自主设计的 第一代战斗机、第一枚运载火箭、第一颗人造卫星……都凝聚着交大师生和校友的心血智慧。 据《新财富》的统计，在针对国内独角兽的统计中， 几乎每 1 5家独角兽（估值超过1 0亿美元 的 初 创 公 司 ） 就 有 1 家 来 自 上 海 交 大 ， 交 大 系 独 角 兽 数 量 排 名 全 国 第 二 。 《 新 财 富 》 更 观 察 道 ： 交 大 系 独 角 兽 企 业 ， 虽 然 其 数 量 不 足 清 华 系 ， 但 估 值 是 清 ...

「解码 LP 」系投资界旗下专注 LP 报道公众号，关注各地基金政策，捕捉 LP 最新动态，欢迎关注！ 根据公开信息统计：截至周四下午，本周（3月29日-4月3日）LP动态共26起。 LP 普洛斯募资，投向一个万亿赛道 投资界获悉，普洛斯最新推出的中国数据中心收益基金一期已完成募集，投资规模约2 6亿 人民币，投资人包括国内领先投资管理公司及知名国际机构投资人，普洛斯担任基金管理人 及资产管理人。 这是普洛斯推出的首个数据中心主题投资策略。普洛斯主要聚焦不动产和私募股权投资，目 前资产管理规模超8 0 0亿美元，已是全球基础设施江湖不可忽视的存在。此次推出的数据中 心基金，是其长期管理运营物流基础设施基金基础上，把私募基金拓展到数据中心这一新的 资产品类，可谓从零到一一个新的突破。 LP 安徽老乡，联手募集3 0亿 一群安徽老乡成立的基金来了。 近日举办的2 0 2 5徽商大会上，3 0亿元徽商产业基金正式启动，由联想、迈瑞、奇瑞、科大 讯飞、蔚来、阳光电源、国轩高科等知名徽商企业联合成立。接下来，该基金将重点投资徽 商科创企业和科创项目。 取自徽商，用之徽商。产业良性循环之风蔚然兴起。近年来，为进一步招商引 ...

Investment Rating - The report maintains a "Buy" rating for WuXi Biologics (2269) [3][8]. Core Insights - The company is actively advancing its "Winning Molecules" strategy, with significant growth in preclinical business and a continuous increase in new projects. The divestment of the Ireland vaccine plant optimizes asset allocation, indicating a positive long-term growth outlook [3][8]. - The company reported a revenue of 18.675 billion RMB for 2024, reflecting a 9.6% increase, while net profit was 3.356 billion RMB, down 1.3%. Adjusted net profit was 5.4 billion RMB, up 9.0% [8]. - The report highlights a strong order and project trend, with 151 new projects signed in 2024, over half of which are from the U.S. The company expects to complete 24 PPQ projects in 2025, a 50% increase from 2024 [8]. Financial Summary - Revenue and profit projections for WuXi Biologics are as follows (in million RMB): - 2022A: Revenue 15,287, Net Profit 4,420 - 2023A: Revenue 17,051, Net Profit 3,400 - 2024A: Revenue 18,675, Net Profit 3,356 - 2025E: Revenue 21,197, Net Profit 4,019 - 2026E: Revenue 24,329, Net Profit 4,706 - 2027E: Revenue 28,278, Net Profit 5,621 - The company’s PE ratio is projected to decrease from 52.51 in 2022 to 18.21 in 2027, indicating improving valuation [7][8].

Investment Rating - The investment rating for the company is "Outperform the Market" [1] Core Views - The report highlights that the company, 康龙化成, has maintained a steady growth in revenue and profit throughout the year, with an accelerating revenue growth rate quarter by quarter. The adjusted profit for Q4 2024 is expected to recover [6][10]. Summary by Sections Financial Performance - In 2023, the company reported a revenue of 11,538 million yuan, with a year-on-year growth of 12.4%. The net profit was 1,601 million yuan, reflecting a 16.5% increase year-on-year. For 2024, the revenue is projected to be 12,276 million yuan, a 6.4% increase, and the net profit is expected to reach 1,793 million yuan, up 12.0% year-on-year [5][6]. Business Segment Performance - **Laboratory Services**: Revenue reached 7,047 million yuan in 2024, growing by 5.8% year-on-year, with a gross margin of 44.4%. The segment saw a 15%+ increase in new orders [6]. - **CMC Business**: Generated 2,989 million yuan in revenue, a 10.2% increase, with a gross margin of 33.1%. New orders grew by 35%+ [6]. - **Clinical Research Services**: Revenue was 1,826 million yuan, up 5.1%, with a gross margin of 12.8%. The segment faced some margin pressure due to increased competition [6]. - **Large Molecule and Cell & Gene Therapy Services**: Revenue declined to 408 million yuan, down 4.1%, with a negative gross margin of 50.1% due to construction investments [7]. Financial Forecasts - The company forecasts revenues of 14,098 million yuan in 2025, 16,104 million yuan in 2026, and 18,250 million yuan in 2027, with respective year-on-year growth rates of 14.8%, 14.2%, and 13.3% [5][10]. - The expected net profits for 2025, 2026, and 2027 are 1,928 million yuan, 2,356 million yuan, and 2,914 million yuan, with growth rates of 7.5%, 22.2%, and 23.7% respectively [10]. Valuation - The report suggests a reasonable valuation range for the company at 32.53 to 37.96 yuan per share, based on a projected PE ratio of 30-35 times for 2025 [10].

Core Insights - The company reported a total revenue of 12.28 billion yuan for 2024, representing a year-on-year growth of 6.4% [1] - The net profit attributable to shareholders reached 1.79 billion yuan, up 12.0% year-on-year, while the adjusted Non-IFRS net profit was 1.61 billion yuan, down 15.6% year-on-year [1] Revenue and Profit Trends - Quarterly revenue showed a recovery trend, with Q1 to Q4 revenues of 2.67 billion, 2.93 billion, 3.21 billion, and 3.46 billion yuan respectively, indicating a year-on-year change of -2.0%, +0.6%, +10.0%, and +16.1% [1] - The adjusted Non-IFRS net profit for Q1 to Q4 was 340 million, 350 million, 420 million, and 500 million yuan respectively, with year-on-year changes of -22.7%, -28.8%, -13.2%, and +1.7% [1] Segment Performance - Laboratory services generated 7.05 billion yuan in revenue, accounting for 57.4% of total revenue, with a gross margin of 44.9% [2] - CMC services achieved 2.99 billion yuan in revenue, representing 24.4% of total revenue, with a gross margin of 33.6% [2] - Clinical research services reported 1.83 billion yuan in revenue, making up 14.9% of total revenue, with a gross margin of 12.8% [2] Market Dynamics - The company experienced a significant increase in new CMC orders, with a year-on-year growth of over 35% [2] - The company successfully commercialized two innovative drug formulations in China and received FDA pre-approval inspection for its Ningbo API production facility [2] Future Outlook - The company is expected to achieve net profits of 1.73 billion, 2.04 billion, and 2.40 billion yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 28, 24, and 20 [3]

Core Viewpoint - The company maintains a "Buy" rating for Hong Kong stocks and raises the target price to HKD 20, while upgrading the A-share rating to "Buy" with a target price of RMB 32 [1][5]. Financial Performance - For Q4 2024, the company's revenue reached RMB 12.276 billion, reflecting a year-on-year increase of 6.4%, aligning with the upper end of the previous profit forecast [2]. - Adjusted net profit attributable to shareholders was RMB 1.607 billion, down 15.6% year-on-year, closely matching the median of the prior profit forecast [2]. - Q4 2024 revenue was RMB 3.458 billion, showing a year-on-year increase of 16.1% and a quarter-on-quarter increase of 7.6% [2]. - The adjusted non-IFRS net profit for Q4 2024 was RMB 499 million, up 1.7% year-on-year and 19.7% quarter-on-quarter [2]. Segment Performance - CMC (Contract Manufacturing and Consulting) services led revenue growth in Q4 2024, achieving a year-on-year growth rate of 26.9% and a quarter-on-quarter growth rate of 26.4% [3]. - Laboratory services also showed significant growth, with a year-on-year increase of 14.9%, although it experienced a slight decline of 1.0% quarter-on-quarter [3]. - Clinical research services saw a year-on-year growth of 9.5% and a quarter-on-quarter growth of 12.4%, despite ongoing pricing pressures [3]. - The CGT (Cell and Gene Therapy) segment continued to show weakness, with both revenue and gross margin declining year-on-year and quarter-on-quarter [3]. Future Outlook - The company expects revenue growth of 10%-15% in 2025, primarily driven by CMC and laboratory services [4]. - Management anticipates potential improvements in profit margins due to sustained revenue growth and no significant additional costs expected [4]. - The new order value for CMC services is projected to grow over 35% year-on-year, while laboratory services are expected to see a growth of over 20% year-on-year [4]. Target Price Adjustments - The target price for Hong Kong stocks has been raised to HKD 20, while the A-share target price has been adjusted to RMB 32, reflecting an 80% premium over the Hong Kong target price [5]. - The adjusted non-IFRS net profit estimates for 2025E and 2026E are RMB 1.79 billion and RMB 2.26 billion, respectively, due to slight adjustments in gross margin forecasts [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown a steady recovery with revenue growth accelerating quarter by quarter, and new orders have increased robustly [3][4] - In 2024, the company achieved operating revenue of 12.276 billion yuan, a year-on-year increase of 6.4%, and a net profit attributable to shareholders of 1.793 billion yuan, up 12.0% year-on-year [3][7] - The company expects net profit attributable to shareholders for 2025-2027 to be 1.771 billion, 2.274 billion, and 2.782 billion yuan respectively, with corresponding EPS of 1.00, 1.28, and 1.56 yuan [3][7] Financial Performance Summary - In 2024 Q4, the company achieved operating revenue of 3.459 billion yuan, a year-on-year increase of 16.2% and a quarter-on-quarter increase of 7.7% [3] - The adjusted Non-IFRS net profit for 2024 Q4 was 500 million yuan, a year-on-year increase of 1.8% and a quarter-on-quarter increase of 19.8% [3] - The laboratory services segment generated revenue of 7.05 billion yuan in 2024, up 5.8% year-on-year, while the CMC business achieved revenue of 2.99 billion yuan, a 10.2% increase year-on-year [4] - The clinical research services segment reported revenue of 1.83 billion yuan in 2024, a year-on-year increase of 5.1% [5] Order Growth and Market Position - The company experienced a robust growth in new orders, with a year-on-year increase of over 20% in 2024 [3] - The CMC segment saw a strong growth in new orders exceeding 35% in 2024 [4] - The company is positioned to benefit from the gradual recovery in the global biopharmaceutical industry [3]

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec, with a target price of 105.56 CNY based on a reasonable valuation level of 29 times the expected earnings per share for 2025 [3][6]. Core Insights - The company has shown a sequential improvement in performance, with a significant increase in backlog orders, which reached 49.31 billion CNY, a year-on-year growth of 47.0%. The TIDES segment saw a remarkable 104% increase in backlog orders [10]. - The revenue for 2024 is projected to recover to double-digit growth, supported by strong demand in the new molecule business and improved operational efficiency [10]. - The company’s revenue for 2023 was 39.24 billion CNY, reflecting a decrease of 2.7% year-on-year, but excluding COVID-19 related projects, the revenue increased by 5.2% [10]. Financial Summary - The expected revenue for 2025 is 42.46 billion CNY, with a year-on-year growth of 8.2%. The net profit attributable to the parent company is projected to be 10.51 billion CNY, reflecting an 11.3% increase [5][10]. - The gross margin is expected to improve to 43.5% in 2025, while the net margin is projected to be 24.8% [5]. - The earnings per share (EPS) for 2025 is estimated at 3.64 CNY, with a projected increase to 4.74 CNY by 2027 [5][10].

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec [6] Core Views - The company has shown a quarter-on-quarter improvement in performance, with a significant increase in backlog orders, which grew by 47% year-on-year to 49.31 billion yuan [10] - The new molecule business (TIDES) has experienced rapid growth, with a year-on-year revenue increase of 57.2%, driven by strong market demand and the company's enhanced capabilities [10] - The company is expected to return to double-digit revenue growth in 2025, supported by robust order backlog and incentive plans for H-share awards [10] Financial Performance Summary - For 2023, the company reported revenue of 40.34 billion yuan, a year-on-year growth of 2.5%, while the adjusted net profit was 9.61 billion yuan, reflecting a 9% increase [5] - The projected revenue for 2025 is 42.46 billion yuan, with an expected net profit of 10.51 billion yuan, indicating a growth of 11.3% [3][5] - The gross margin is expected to improve to 43.5% in 2025, while the net margin is projected to be 24.8% [5] Valuation and Price Target - The report estimates a reasonable valuation for the company at a price-to-earnings ratio of 29 times for 2025, leading to a target price of 105.56 yuan [3] - The current share price is noted at 68 yuan as of March 27, 2025 [6] Market Performance - The stock has shown a 49.64% increase over the past 12 months, outperforming the market [7]

Financial Performance - Pharmaron reported a revenue increase of 25% year-over-year, reaching approximately RMB 2.5 billion in the latest quarter[18]. - The company's operating revenue for 2024 reached ¥12,275,774,875.03, representing a 6.39% increase compared to ¥11,537,996,314.78 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥1,793,350,814.50, marking a 12.01% increase from ¥1,601,096,033.08 in 2023[23]. - The company reported a basic earnings per share of ¥1.0133 for 2024, up 12.18% from ¥0.9033 in 2023[23]. - The company achieved operating revenue of 1,227,577.49 million yuan, a year-on-year increase of 6.39%[42]. - The company reported a decline in cash flow from operating activities, totaling 257,665.64 million yuan, down 6.42% year-on-year[42]. - The company reported a net cash flow from operating activities of ¥2,576,656,397.08 in 2024, down 6.42% from ¥2,753,538,934.89 in 2023[23]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion, representing a 20% year-over-year growth[176]. Research and Development - Pharmaron's R&D investment increased by 30% to RMB 500 million, focusing on new drug development and innovative technologies[18]. - The company has expanded its capabilities in antibody-drug conjugates (ADC) and antisense oligonucleotides (ASO) as part of its research and development strategy[15]. - The company is actively exploring the application of artificial intelligence and machine learning in process chemistry R&D and quality management to enhance CDMO service efficiency[53]. - The company is committed to enhancing its ESG initiatives, focusing on sustainable practices in its operations[18]. - The company is focused on enhancing its research and development capabilities to better meet customer needs[115]. - The company is committed to improving high-quality, diverse biomedical databases and constructing reliable AI models, ensuring the sustainability of AI-enabled drug development[134]. Market Expansion and Strategy - Pharmaron is actively pursuing market expansion in Europe and North America, aiming to increase its global footprint[18]. - The company is continuously exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position[15]. - The company plans to strengthen its leadership in small molecule R&D services while expanding into new drug modalities such as ADCs and peptides, with a focus on building an end-to-end service platform[121]. - The company aims to enhance collaboration across its multi-therapy platform, focusing on seamless integration in drug development stages and improving service quality through interdisciplinary cooperation[125]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[175]. Corporate Governance and Compliance - The company emphasizes the importance of accurate financial reporting, with all board members present for the approval of the annual report[3]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring transparency in information disclosure[147]. - The company received an "A" rating in the information disclosure assessment from the Shenzhen Stock Exchange, reflecting its commitment to high-quality and transparent reporting[142]. - The company has established a comprehensive risk management framework to address various financial risks[1]. - The company is committed to maintaining a high standard of compliance with international regulations and quality standards to ensure the integrity of its services[126]. Employee Development and Corporate Culture - The company emphasizes a strong commitment to employee development and customer satisfaction, integrating personal career growth into the overall corporate strategy[73]. - The company has established a comprehensive talent management system to attract and retain skilled professionals, crucial for sustaining its competitive edge[128]. - The company has implemented a comprehensive compensation policy to attract and retain talent, including competitive salaries, bonuses, and various benefits[198]. - Training programs are tailored for different management levels, focusing on leadership development and performance improvement[199][200]. - The company emphasizes mental health and well-being through various employee support programs[198]. Financial Strategy and Investments - The company plans to distribute a cash dividend of 2 RMB per 10 shares, totaling approximately 356.11 million RMB for the 2023 fiscal year[144]. - The company will repurchase 9,608,288 A shares for a total amount of approximately 200.09 million RMB in 2024[145]. - The company has not utilized any raised funds during the reporting period[112]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $100 million allocated for potential deals[176]. - The company is implementing hedging strategies to manage foreign exchange risks effectively[131]. Environmental and Social Responsibility - The company is actively responding to the national "dual carbon" strategy, focusing on reducing its environmental impact and promoting green transformation within its operations[142]. - The company reduced greenhouse gas emissions by 21% in 2024 compared to 2023, achieving its annual carbon reduction target[47]. - The company is committed to enhancing its ESG initiatives, focusing on sustainable practices in its operations[18]. Risk Management - The company has established a comprehensive risk management framework to address various financial risks[1]. - The company is actively monitoring international policy changes and trade dynamics to mitigate risks associated with geopolitical uncertainties[130]. - The company acknowledges potential risks in the drug development service market due to fluctuations in investment and budget changes from multinational pharmaceutical companies[127]. - The company faces risks related to intellectual property protection and is enhancing its confidentiality measures to safeguard client information[129].